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Although originally synthesized as an anti-estrogen, tamoxifen (Tam) was found to be able to inhibit proliferation of estrogen receptor (ER)-negative cancer cells in vitro. However, the molecular basis of such ERindependent growth inhibition is largely unknown. We have previously demonstrated that Tam induces p21 WAF1 and p27 KIP1 expression in human lung cancer cells which lack ER-a and -b. We found that Tam induced p21 WAF1 expression via transcriptional activation. In order to determine the molecular mechanism responsible for p21 WAF1 induction by Tam, we performed a deletion analysis on the p21 WAF1 promoter. The minimal region in the p21 WAF1 promoter required for Tam-activated induction was mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site. Our results showed that transcription factor Sp1 and Sp3 bound to this GC-rich region and mutation of Sp1-binding sites dramatically attenuated Tam-induced  p21 WAF1 promoter activity. We also tried to elucidate the signaling pathway that mediated the activation of p21 WAF1 by Tam. Inhibition of mitogen-activated protein kinase pathways did not block Tam-induced p21   WAF1 . Similarly, protein kinase C inhibitor calphostin C could not suppress Tam-induced p21   WAF1 . Conversely, pretreatment of a speci®c protein kinase A inhibitor H89 signi®cantly attenuated the induction of p21 WAF1 by Tam. Furthermore, PKA activators forskolin and dibutyryl-cAMP activated p21 WAF1 promoter activity and increased p21 WAF1 protein level in lung cancer cells. Taken together, these results demonstrate that Tam activates the p21 WAF1 promoter via Sp1-binding sites and suggest that PKA may be involved in the induction of p21 WAF1 Introduction Tamoxifen (Tam), a synthetic anti-estrogen, is widely used for the treatment of breast cancer (Furr and Jordan, 1984; Jordan et al., 1991; Henderson et al., 1992) . Additionally, clinical studies indicated that Tam may reduce the risk of invasive breast cancer and may be used as a chemopreventive agent in women at increased risk for the disease (Fisher et al., 1998) . Moreover, this drug was reported to exert an anticancer eect on a number of estrogen receptor (ER)-negative cancer cells, including lung cancer, brain tumor and melanoma (Croxtall et al., 1994; Couldwell et al., 1993; DelPrete et al., 1984) . However, the molecular mechanism of such ER-independent growth inhibition is largely unknown. We have demonstrated that inhibition of growth of ER-negative human lung cancer cells by Tam is associated with the induction of cyclin-dependent kinase inhibitors (CDKIs) p21 WAF1 and p27
KIP1 (Lee et al., 1999) . We found that upregulation of CDKIs in lung cancer cells by Tam led to reduced activity of cyclin E-associated kinases, accumulation of hypophosphorylated retinoblastoma (Rb) protein and G1 growth arrest in these cells. Our results also indicated that Tam induced p21 WAF1 expression through transcriptional activation. However, the critical elements in the p21 WAF1 promoter required for induction by Tam is not clear at present.
In addition, the signaling pathway that mediated Tam-induced p21   WAF1 expression is also unknown. Classically, Tam is thought to inhibit growth of ERpositive cancer cells by blocking the binding of estrogen to ER and thus inhibiting the expression of estrogen-responsive genes (Jordan and Murphy, 1990 (Cobb and Goddsmith, 1995; Marais et al., 1993; Gupta et al., 1995) . These kinases were found to be involved in regulation of proliferation, apoptosis and dierentiation in dierent cell types (Ip and Davis, 1998) . It is possible that Tam may aect cell cycle progression by modulating the activation of MAPK cascade. Second, Tam was found to inhibit protein kinase C (PKC) in human cancer cells (O'Brian et al., 1986) . PKC plays a crucial role in the promotion of cell growth and a close link between PKC signaling pathway and cell cycle control has been suggested (Livneh and Fishman, 1997) . Therefore, investigation of the functional role of PKC in Tam-induced p21   WAF1 expression seems warrantable. Finally, Tam was reported to suppress the enzymatic activity of calmodulin-dependent cyclic AMP (cAMP) phosphodiesterase in cells (Rowlands et al., 1990) . These data suggest that cAMP/PKA pathway may be a potential target for the anti-cancer action of Tam.
In this study, we performed a functional analysis on the p21 WAF1 promoter and investigated the functional role of the aforementioned signaling pathways in the induction of p21 WAF1 by Tam. Our results indicate that Tam activates p21 WAF1 gene expression via Sp1-binding sites in the p21 WAF1 promoter and suggest that PKA may be involved in this process.
Results

Identification of Tam-responsive elements in the p21
WAF1 promoter
To determine the regions in the p21 WAF1 promoter responsible for transcriptional activation by Tam, a series of 5'-deletion mutants based on the 2.4 Kb p21 WAF1 promoter were transfected into H358 cancer cells and Tam-induced promoter activity was measured. As shown in Figure 1 , the full-length promoter construct, p21P, was activated 3.5-fold by Tam. Constructs consisting of 1.6 Kb, 1.1 Kb, 300 bp or 100 bp proximal to the transcription start site were fully responsive to Tam. Additionally, a construct, p21P93-S, harboring the promoter sequence between bp 793 and 749 was activated by Tam to a similar extent as p21P. In contrast, the minimal promoter construct, p21PSmaD1, which containing only 61 bp proximal to the transcription start site was not activated by Tam. Thus, the Tam-responsive element is located in a 32-bp region between 793 and 762 in the p21 WAF1 promoter.
Mutation of Sp1-binding site in the p21P93-S construct abolishes Tam-induced luciferase activity
The 32-bp region between 793 and 762 in the p21
WAF1
promoter was reported to be a GC-rich region and contained two Sp1-binding sites. The Sp1 site between 784 and 778 has been identi®ed as a transforming growth factor-b (TGF-b)-responsive element and a butyrate-responsive element (Datto et al., 1995; Nakano et al., 1997) . To further characterize the critical elements necessary for the induction of Tam, we tested two constructs of p21P93-S (p21P93-S mut#2 and mut#3) in which the two Sp1 sites were mutated (Datto et al., 1995) . Our results demonstrated that Tam activated p21P93-S mut#3, which contained a mutated Sp1 site located between bp 773 and 764, to a level similar to that of wild-type p21P93-S (Figure 2 ). Conversely, mutation of the Sp1 site located between bp 783 and 774 (p21P93-S mut#2) signi®cantly reduced the luciferase activity induced by Tam. These results suggest that this promoter region is necessary for the induction of p21 WAF1 by Tam. We next studied the eect of Tam on another two mutant promoter constructs to con®rm the result. p21P93-S mut#2.2 construct which has mutations of bp 778 and 779 from CC to AG, or p21P93-S mut#2.3 construct which WAF1 promoter. Wild-type or mutant constructs of the p21P93-S promoter reporter construct were transfected into H358 cells and cells were incubated with vehicle (0.2% ethanol, &) or Tam (10 mM, &) for 24 h and Taminduced luciferase activity was measured. The constructs p21P93-Smut#2 and p21P93-Smut#3 contains a mutated Sp1 site located between bp 783 and 774 or bp 773 and 764 proximal to the transcription start site respectively. The p21P93-Smut#2.2 construct has a mutation of bp 779 and 778 from CC to GA in wild-type p21P93-S sequence and the p21P93-S mut#2.3 construct has a mutation of bp 777 and 776 from TC to GG in wild-type p21P93-S sequence. Results shown are from three independent experiments has mutations of bp 776 and 777 from CT to GG, was transfected into H358 cells and the luciferase activity was measured. As shown in Figure 2 , these two promoters did not respond to Tam. Taken together, these data indicate that Tam activates p21 WAF1 expression via the Sp1 site located between bp 783 and 774 in the p21 WAF1 promoter.
Characterization of the nuclear factors that interact with the Sp1 site located between bp 783 and 774 in the p21 WAF1 promoter
To determine whether increased promoter activity induced by Tam was due to changes in binding of nuclear proteins to the Sp1 site located between bp 783 and 774, EMSAs were performed with oligonucleotides corresponding to the region (783/ 774) of wild-type promoter constructs. One major DNA-protein complex was detected. Both the mobility pattern and intensity of this band were not changed by Tam treatment ( Figure 3a ). These data suggested that Tam treatment did not alter DNA binding activity of nuclear proteins. Additionally, binding of nuclear proteins to the (783/774) region is sequencespeci®c because the major band could be competed away by an excess of unlabeled wild-type oligonucleotides, but not by an excess of two unlabeled mutated oligonucleotides corresponding to mut#2.2 or mut#2.3 ( Figure 3b ). Previous studies have shown that Sp1 or Sp3 transcription factor bound to the (783/774) region in the p21 WAF1 promoter concomitantly in a number of cell types (Billon et al., 1999; Prowse et al., 1997 ). Thus, we tested whether the nuclear factors that bound to this region in control or Tam-treated H358 cells are Sp1-related proteins. As shown in Figure 4 , addition of Sp1 or Sp3 antibody led to supershift of the complex. On the contrary, addition of pre-immune immunoglobulin did not aect the mobility of the complex. These data indicate that both Sp1 and Sp3 bind to the Sp1 site located between bp 783 and 774 in the p21 WAF1 promoter.
Inhibition of MAPK or PKC signaling pathway does not block Tam-induced p21 WAF1 expression
We next studied the signaling pathway that mediated the induction of p21 WAF1 by Tam. Luciferase activity assay and Western blot analysis were performed to answer this question. A previous study showed that Tam stimulated ERK2 and JNK1 activity in cells (Duh et al., 1997), therefore we investigated whether Taminduced p21 WAF1 expression is mediated by MAPK signaling pathway. Two chemical inhibitors were used to block the activity of MAPK-related kinases. PD98059 is a speci®c inhibitor for MAP kinase kinase (MEK), and SB203580 is a selective inhibitor for p38 HOG1 kinase. As demonstrated in Figure 5a , pretreatment of these two inhibitors did not attenuate Tam-induced luciferase activity. Additionally, Western blot analysis also indicated that induction of p21 WAF1 by Tam was not inhibited by PD98059 or SB230580 (Figure 5b ). These results are not surprising, because the concentration of TAM needed to activate ERK2 or JNK1 is higher than 100 mM, while only 10 mM of TAM is needed to stimulate the expression of p21 WAF1 .
These results suggest that MAPK signaling pathway is not involved in Tam-induced p21   WAF1 . We next investigated the role of PKC in the induction of p21 WAF1 by Tam. As shown in Figure 6a , pretreatment of calphostin C, a speci®c PKC inhibitor, could not suppress Tam-activated promoter activity. In addition, Tam-induced p21 WAF1 was not attenuated by calphostin C (Figure 6b ). Although Tam was reported to be a PKC inhibitor and a recent study showed that a nonspeci®c PKC inhibitor staurosporine induced p21 WAF1 expression in a bladder carcinoma cell line (Rohl et al., 1998) , it is unlikely that Tam induces p21 WAF1 via inhibition of PKC. First, as shown in Figure 6a ,b, treatment of calphostin C alone did not signi®cantly activate p21 WAF1 promoter activity or increase p21 WAF1 protein level in H358 cells. Second, the concentration of calphostin C (5 mM) used in this study completely blocked the PKC activity in cells. However, Tam still eectively induced p21 WAF1 expression under this condition. Therefore, we suggest that Because Tam was demonstrated to inhibit calmodulindependent cAMP phosphodiesterase and to increase intracellular cAMP levels in a number of cell types, we tested whether PKA plays a role in the induction of p21 WAF1 by Tam. Our results showed that the selective PKA inhibitor H89 suppressed the promoter activity of p21 WAF1 activated by Tam (Figure 7a ). Moreover, increase of p21 WAF1 protein triggered by Tam was also attenuated by preincubation of H89 (Figure 7b ). These data indicate that Tam-induced p21 WAF1 expression may be mediated by the cAMP/PKA pathway. To further con®rm the aforementioned results, we studied the eect of two PKA activators, forskolin and dibutyrylcAMP, on the promoter activity of p21
. As demonstrated in Figure 8a , forskolin or dibutyrylcAMP induced 3.2-to 3.8-fold increase of luciferase activity in H358 cells. Additionally, in accordance with the results of Figures 1 and 2 , forskolin and dibutyrylcAMP induced p21 WAF1 via the Sp1 site located between bp 783 and 774 in the p21 WAF1 promoter (Figure 8b ). These two activators also increased p21 WAF1 protein level in these cells (Figure 8c ). Considered together, these results suggest that PKA may be involved in Tam-induced p21 WAF1 expression in ER-negative cancer cells.
Discussion
Our previous study has demonstrated that Tam may induce p21 WAF1 and p27
KIP1 in an ER-independent manner (Lee et al., 1999) . In this study, we show that Tam activates p21 WAF1 expression through Sp1-binding site located between bp 783 and 774 in the p21 WAF1 promoter. Several transcription factor binding sites such as Ap-2 (Zeng et al., 1997) , STATs (Chin et al., 1996) , C/EBP (Cram et al., 1998; Chinery et al., 1997) , RAR (Liu et al., 1996) and Sp1 (Datto et al., 1995; Nakano et al., 1997; Lee et al., 1998; Biggs et al., 1996; Owen et al., 1998; Billon et al., 1999) were known to mediate the induction of p21 WAF1 by many extracellular signals. Interestingly, the Sp1 site located between bp 783 and 774 in the p21 WAF1 promoter has been reported to be activated by TGF-b1, butyrate, lovastatin, phorbol ester, nerve growth factor (NGF) and progesterone (Datto et al., 1995; Nakano et al., 1997; Lee et al., 1998; Biggs et al., 1996; Owen et al., 1998; Billon et al., 1999) . These results indicate that this Sp1 site is a critical region in the regulation of p21 WAF1 expression in response to extracellular stimuli. Additionally, up-regulation of p21 WAF1 by these stimuli is not dependent on p53. Study of Sp1-regulated p21 WAF1 expression is important for elucidation of p53-independent signaling pathway in the regulation of p21 (Datto et al., 1995; Nakano et al., 1997; Biggs et al., 1996; Owen et al., 1998; Billon et al., 1999) . Sp1 and Sp3 are ubiquitous transcription factors that recognize GC-rich sequences present in many promoters (Azizkhan et al., 1993) . Regulation of Sp1-dependent transcription could be modulated by alterations in Sp1 abundance, DNA binding activity and transcription activity. Because protein level and DNA binding activity of Sp1 were not changed by Tam treatment (unpublished data and Figure 3a) , it is suggested that Tam may enhance the transcription activity of Sp1 or Sp3 to activate p21 WAF1 expression. Recent studies demonstrated that Sp1-mediated transcriptional activation could be regulated by phosphorylation (Armstrong et al., 1997; Daniel et al., 1996; Rohl et al., 1997) . Phosphorylation of Sp1 by casein kinase 2 (CK2) resulted in down-regulation of its DNA binding activity and in reduction of transcription (Armstrong et al., 1997) . DNA-dependent protein kinase could phosphorylate Sp1 but did not aect its DNA binding activity or Sp1-dependent transcription (Jackson et al., 1990) . Conversely, ERK2 and PKA could phosphorylate Sp1 and stimulate its DNA binding and transcription activity (Merchant et al., 1999; Rohl et al., 1997) . Because Tam-induced p21 WAF1 expression may be mediated by PKA and the transcription activity of Sp1 could be activated by PKA, it seems rational to speculate that Tam may activate the cAMP/PKA signaling pathway to induce Sp1 phosphorylation and subsequently induce Sp1-dependent p21 WAF1 expression in H358 cells. In fact, mediation of cAMP-induced transcription by Sp1-related transcription factors is not uncommon. For example, a crucial role for Sp1 in cAMP-dependent transcription of the CYP11A gene has been demonstrated recently (Ahlgren et al., 1999) . Another study also demonstrated that transcriptional regulation of neuro®lament expression by PKA in an immortalized neuronal cell line is mediated via Sp1-like nuclear factors (White et al., 1997) .
However, our speculation may be too simple. First, although both Tam and PKA activators could eectively activate p21 WAF1 promoter activity, the kinetic of activation is dierent. Tam induced p21 WAF1 expression in a time-dependent manner. However, we found that PKA activators induced a biphasic induction of p21
WAF1
. Short-term incubation of PKA activators (4 h) stimulated p21 WAF1 promoter activity, while long-term treatment (24 h) did not signi®cantly increase p21 WAF1 promoter activity (data not shown). This is also the reason why the time of stimulation for forskolin and dibutyryl-cAMP was chosen to be 4 h rather than 24 h in our study. Interestingly, a similar T-H Lee et al observation has also been reported in human breast cancer cells (Rao et al., 1999) . The authors found that p21 WAF1 mRNA in human breast cancer cells peaked at 4 to 6 h after addition of cAMP modulators and gradually diminished, returning to basal level by 12 h. These results suggest that action of Tam in the induction of p21 WAF1 is dierent from that of PKA activators. At present, the molecular basis for this biphasic induction is not known. Second, as described in Introduction, Tam may raise intracellular cAMP level by inhibiting cAMP-dependent phosphodiesterase and increased cAMP may subsequently activate PKA in cells. However, recent studies showed that cAMP may aect cellular functions via PKA-dependent and -independent signaling pathways (Cass et al., 1999; Rao et al., 1999) . Although our results showed that H89 suppressed Tam-induced p21   WAF1 , the possibility that this drug may also inhibit other signaling pathways in cells could not be ruled out. In order to answer the functional role of PKA in Tam-induced p21   WAF1 , we are now creating stable transfectants in which dominant-negative mutants of PKA will be overexpressed and testing the eect of Tam in the induction of p21 WAF1 in these cells. Additionally, although Sp1 and Sp3 transcription factors were identi®ed to be the nuclear proteins that interact with the Tam-responsive elements in the p21 WAF1 promoter, the mechanism by which Tam activates the transcription activity of these transcription factors is not clear. If Tam indeed activates the transcription activity of Sp1 or Sp3 transcription factors via protein phosphorylation, identi®cation of the critical phosphorylation sites will be helpful for the understanding of the functional role of Sp1-related transcription factors in the induction of p21 WAF1 by Tam. Furthermore, it is possible that these studies may lead to the identi®cation of a common pathway by which extracellular signals (such as TGFb1, butyrate etc.) control p21 WAF1 expression via Sp1-related proteins. However, because Sp1 is a multiply phosphorylated protein, this will be a big project for future investigation.
Recent studies have shown that p21 WAF1 expression is a predictor for favorable prognosis for NSCLC patients (Komiya et al., 1997; Caputi et al., 1998; Bennett et al., 1998) . Additionally, more than 70% of NSCLC tumors showed reduced p27 KIP1 immunoreactivity and the expression of this CDKI was found to be a favorable prognostic factor for patient survival (Yatabe et al., 1998; Catzaveles et al., 1999) . Since p21 WAF1 and p27 KIP1 appear to be rarely mutated in human lung tumors, it is possible that activation of these two growth-inhibitory genes by Tam may be helpful for the treatment of lung cancer. In addition to our study, induction of p21 WAF1 and inhibition of proliferation by Tam in human pancreatic and prostate cancer cells which do not express ER have also been reported recently (Robinson et al., 1998; Rohl et al., 1998) . Therefore, Tam may be a potential drug for chemoprevention of a variety of ER-negative human cancers. Indeed, a very recent study has clearly demonstrated that Tam can prevent the occurrence of hormone-independent and Neu/HER2-overexpressing breast cancer in a mouse model (Menard et al., 2000) . Taken together, our results provide a molecular basis for the anti-cancer eect of Tam on ER-negative cancer cells and suggests that Tam may be a potential drug for treatment or prevention of lung cancer.
Materials and methods
Cell culture and reagents
H358 human lung cancer cells were cultured in Dulbecco's modi®ed Eagle's medium and F12 nutrition mixture (DMEM/F12) supplemented with 10% fetal calf serum (FCS) and antibiotics. SB203580, PD98059, H89 and calphostin C were purchased from Calbiochem (La Jolla, CA, USA). The p21 promoter reporter construct WWP-luc was kindly provided by Dr B Vogelstein. Serial deletion of p21 WAF1 promoter reporter constructs p21PD800, p21PD1.1, p21PD2.1, p21PD2.3, p21PSma, p21P93-S, p21PSmaD1 and the mutant p21 promoter constructs p21P93-S mut#2, p21P93-S mut#3, p21P93-S mut#2.2, and p21P93-S mut#2.3 were described previously (Datto et al., 1995) and were kindly provided by Dr XF Wang. The luciferase assay system was from Promega (Madison, WI, USA). Monoclonal antibody against human p21 WAF1 was purchased from Transduction Laboratories (Lexington, KY, USA). Forskolin, dibutyrylcAMP and other chemicals were obtained from Sigma (St. Louis, MI, USA).
Luciferase assays
Cells were plated onto 6-well plates at a density of 100 000 cells/well and grown overnight. Cells were transfected with 2 mg of plasmids with the LipofectAMINE method as described previously (Lee et al., 1999) . Cells were pretreated with inhibitors for 1 h and were incubated with vehicle (0.2% ethanol) or Tam (10 mM) for 24 h, and luciferase activities were assayed. Luciferase activities were normalized for the amount of protein in cell lysates and were calculated as an average of three independent experiments of duplicate samples. For stimulation of dibutyryl-cAMP or forskolin, cells were transfected with 2 mg of plasmids and incubated with forskolin (10 mM) or dibutyryl-cAMP (1 mM) for 4 h and luciferase activities were determined.
Immunoblotting
Cells were plated onto 6-well plates at a density of 100 000 cells/well and grown overnight. Cells were pretreated with dierent inhibitors in 10% FCS medium for 1 h and then stimulated with Tam (10 mM) for another 24 h. After stimulation, cells were washed with cold phosphate-buered saline (PBS) and harvested with a lysis buer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl¯uoride (PMSF), 1 mg/ml aprotinin, 2 mg/ ml pepstatin A and 2 mg/ml leupeptin) for 20 min on ice. Cell lysates were centrifuged at 12 000 g for 10 min and protein concentrations of the lysates were determined by using a BCA protein assay kit (Pierce, IL, USA). Cell lysates (20 mg protein/sample) were then subjected to sodium dedocyl sulphate-polyacrylamide gel electrophoresis (SDS ± PAGE). Proteins were transferred to nitro-cellulose membranes and the blots were blocked in 5% non-fat milk in TBST (20 mM Tris-HCl, pH 7.4, 137 mM NaCl and 0.05% Tween-20) overnight at 48C. The blots were washed in TBST and incubated with p21 WAF1 monoclonal antibody for 2 h at room temperature. After incubation, the blots were washed three times in TBST and incubated with peroxidase-conjugated secondary antibody for another 1 h. Finally, the blots were developed by using the ECL chemiluminescence system (Amersham Pharmacia Biotech).
Oligonucleotide synthesis and labeling
Complementary oligonucleotides corresponding to bases 771 through 786 of wild-type p21 WAF1 promoter, p21P93-S mut#2.2 and p21P93-S mut#2.3 were synthesized (71 ± 86 wt, GGTCCCGCCTCCTTGA and TCAAGGAGGCGGG-ACC; 71 ± 86 mut#2.2, GGTCCCGGATCCTTGA and TCA-AGGATCCGGGACC and 71 ± 86 mut#2.3, GGTCCCGCC-GGCTTGA and TCAAGCCGGCGGGACC). 200 ng of wild-type oligonucleotides were end-labeled with g-32 P-ATP by using a 5'-end labeling system (Promega, WI, USA).
Nuclear extract preparation and electrophoretic mobility shift assay (EMSA) Preparation of nuclear extracts from control or Tam-treated H358 cells were carried out as described previously (Andrews and Faller, 1991) . In brief, H358 cells were plated in 75 cm 2 asks and grown to 70 ± 80% con¯uence. Cells were incubated in the absence or presence of 10 mM of Tam for dierent times. Cells were washed with cold PBS and lysed in cold buer A (10 mM HEPES-KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM dithiothreitol, 0.2 mM PMSF). Cells were then spun down and extracted in cold buer C (20 mM HEPES-KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, and 0.2 mM PMSF) on ice for 20 min. Cellular debris was clari®ed and protein concentrations were determined. EMSAs were routinely performed at 48C. The reaction mixture for EMSA contained 20 mM Tris-HCl, pH 7.6, 1 mM dithiothreitol, 2 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 0.1% NP-40, 1 mg of poly(dI-dC) and 5 ± 8 mg of nuclear extract. Non-labeled speci®c competitors or antibodies were added and incubated for 10 min. 32 P-labeled probe DNA (50 000 c.p.m.) was added to the mixture and the binding reaction was allowed to proceed at 48C for another 20 min. The mixtures were resolved on 0.56TBE, 6% polyacrylamide gel at 200 V for 2 h. Gels were dried and autoradiography was performed.
